A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization
2011

Polypill for Preventing Heart Disease: A Study in Sri Lanka

Sample size: 216 publication Evidence: moderate

Author Information

Author(s): Soliman Elsayed Z, Mendis Shanthi, Dissanayake Wasantha P, Somasundaram Noel P, Gunaratne Padma S, Jayasingne I Kumudini, Furberg Curt D

Primary Institution: Wake Forest University School of Medicine

Hypothesis

Can a Polypill effectively reduce cardiovascular disease risk factors in patients without established CVD?

Conclusion

The study showed high acceptability of the Polypill among patients and physicians, but no significant differences in risk factor reductions compared to standard treatment.

Supporting Evidence

  • 94% of patients completed the trial and expressed willingness to take the Polypill for life if effective.
  • 86% of physicians supported the use of the Polypill for primary prevention of CVD.
  • Both treatment groups showed reductions in systolic blood pressure and cholesterol, but no significant differences were found.

Takeaway

The Polypill combines several medications to help prevent heart disease, and many patients liked the idea of taking it if it works.

Methodology

An open-label, parallel-group, randomized clinical trial conducted in Sri Lanka with 216 patients without established CVD.

Potential Biases

The open-label design may have influenced treatment outcomes due to the high level of care provided to the control group.

Limitations

The control group received similar treatments, making it hard to measure the Polypill's effectiveness.

Participant Demographics

Patients were primarily over 50 years old, with a mix of genders and varying CVD risk levels.

Digital Object Identifier (DOI)

10.1186/1745-6215-12-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication